1. Home
  2. Companies
  3. ATH
  4. Material Events

Alterity Therapeutics (ASX:ATH) — Material Events

ASX:ATH · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 15 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
Alterity Therapeutics Secures FDA Nod for Single Phase 3 Trial in Multiple System AtrophyHigh
Alterity Therapeutics secures FDA Phase 3 pathway for ATH434 in MSA, plans trial start by end 2026
30 July 2026 ·Quarterly Cash Flow Report and Corporate Update ·85
Alterity Therapeutics Secures FDA Green Light for ATH434 Phase 3 Trial in Multiple System AtrophyMedium
Alterity Therapeutics Secures FDA Alignment on Phase 3 Trial Design for ATH434 in Multiple System Atrophy
9 June 2026 ·Clinical Trial Update ·85
Alterity’s ATH434 Shows Promise in Slowing Multiple System Atrophy ProgressionMedium
Alterity Therapeutics reports positive Phase 2 results for ATH434 in Multiple System Atrophy
15 Sept 2025 ·Clinical Trial Data Presentation ·85
Alterity Therapeutics Reports Larger Losses Amid FDA Phase 3 Trial Clarity for ATH434Medium
Alterity Therapeutics reports increased revenue, larger net loss, and FDA-aligned Phase 3 trial plan for ATH434 in MSA
28 Aug 2026 ·Annual Report and Audited Financial Statements ·85
Alterity Therapeutics Secures US Patent Extending ATH434 Protection to 2045Medium
Alterity Therapeutics secures US patent for ATH434 extending protection to 2045, advancing Phase 3 plans
12 Aug 2026 ·Patent Grant Announcement ·85
Alterity Advances ATH434 to Phase 3 with Promising MSA Trial DataMedium
Alterity Therapeutics Advances ATH434 to Phase 3 for Multiple System Atrophy Following Positive Phase 2 Data
19 May 2026 ·Clinical Trial Update ·85
Alterity Strengthens ATH434 Data, Eyes FDA Phase 3 Nod with $49M Cash BufferMedium
Alterity Therapeutics advances ATH434 with strong Phase 2 data, FDA Phase 3 planning, and solid cash position
30 Jan 2026 ·Appendix 4C Quarterly Cash Flow Report & Corporate Update ·85
FDA Confirms Single Phase 3 Trial Pathway for Alterity’s ATH434 in MSAMedium
FDA Confirms Registrational Pathway for Alterity's ATH434 in Multiple System Atrophy
7 July 2026 ·Regulatory Update ·85
Alterity Advances ATH434 Phase 3 Program with FDA Alignment and New Clinical DataMedium
Alterity Therapeutics advances ATH434 Phase 3 plans with FDA alignment and strong clinical data, holds A$44.53M cash
30 Apr 2026 ·Quarterly Cash Flow Report and Corporate Update ·85
Alterity Advances ATH434 with Strong Phase 2 Data and $2.4B Market PotentialMedium
Alterity Therapeutics reports positive Phase 2 data for ATH434 in MSA and secures A$54.56M cash with $2.4B market potential
31 Oct 2025 ·Appendix 4C Quarterly Cash Flow Report ·85
Alterity’s ATH434 Shows Functional Benefit in MSA Using New Composite ScaleMedium
Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Multiple System Atrophy
22 Apr 2026 ·Clinical Trial Data Presentation ·85
Alterity Therapeutics Advances ATH434 Phase 3 with Positive FDA FeedbackMedium
Alterity Therapeutics Secures Positive FDA Feedback on ATH434 Phase 3 Program
30 Mar 2026 ·Regulatory Update ·80
Alterity Therapeutics Secures A$20M to Propel ATH434 Toward FDA ApprovalMedium
Alterity Therapeutics Raises A$20M in Strategic Placement to Advance ATH434 Clinical Development
8 Sept 2025 ·Capital Raising ·80
Alterity Advances ATH434 Phase 3 Program with FDA Endorsement on ManufacturingMedium
Alterity Therapeutics Secures Positive FDA Feedback on ATH434 Phase 3 Program for MSA
27 Apr 2026 ·Regulatory Update ·75
Alterity Therapeutics Secures Up to A$7.96 Million Through Underwritten ATHO OptionsMedium
Alterity Therapeutics secures underwriting for ATHO options to raise up to A$7.96 million
31 Aug 2026 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.